OBJECTIVE: To assess the effectiveness of hydroxychloroquine (HCQ) on knee osteoarthritis (OA). METHODS: Two groups of patients with OA diagnosis have been assessed in a controlled, randomic, double-blind study, the first group consisted of 16 patients who received the therapeutics with HCQ, with the dosage of 400 milligrams per day during four months and the other one consisted of 13 patients who received the placebo during the same period of time. Both groups were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Lequèsne Algofunctional Index and the Visual Analogue Scale (VAS). RESULTS: There was not any difference between the groups on the WOMAC subscales in relation to the pain (p=0,551), stiffness (p=0.512) and function (p=0.293). On the VAS and Lequèsne scale, there was not any difference statistically significant with p=0.461 and p=0.803 respectively. CONCLUSION: Although both groups have presented improvement, there was not superiority on the knees' OA treatment in the group which underwent HCQ use in relation to the placebo group in this study.
osteoarthritis; knee; hydroxychloroquine; clinical trial
